CheckMate-577: Odivo aids therapy for esophageal cancer and gastric esophageal connecting cancer patients can significantly improve disease-free survival.

On September 21, 2020, NYSE: BMY today announced the first round of clinical results of Phase III clinical trial CheckMate-577.
results showed that Odivo (Navuliyu monoantigen) showed statistically significant and clinically significant improvements in esophageal and gastroesophageal connection cancer patients with new assisted synchrugal chemotherapy (CRT) and surgical excision compared to placebo.
, the standard treatment for patients with esophageal cancer and gastroesophageal connecting cancers who have underwent new assisted simultaneous chemotherapy and surgical removal is surveillance follow-up.
results confirm for the first time that complementary therapy can significantly extend the disease-free survival of such patients.
compared to the placebo group of 11.0 months; (95% confidence interval: 8.3 to 14.3) in the patient group who received Odivo treatment after surgery, the medium DFS was doubled, and (22.4 months) 95 % CI: 16.6 to 34.0) (risk ratio: 0.69; 96.4% CI: 0.56 to 0.86; p=0.0003).
in the Odivo group had a medium duration of more than 10 months . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
in the CheckMate-577 study, the safety of Odysseotherapy was consistent with previous studies.
" Although about 25-30% of patients with esophageal cancer and gastroesophageal connectivity cancer can achieve complete remission after simultaneous chemotherapy and surgical removal, 70-75% of patients still fail to reach.
for these patients, there is currently no complementary treatment option to improve their effectiveness.
"Dr. Ronan J. Kelly, Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, said, "According to the CheckMate-577 study, patients treated with Odivo's assisted treatment doubled their disease-free survival, the first breakthrough in complementary therapy in the field of esophageal cancer and gastroesophageal cancer."
" is good for safety and tolerance compared to placebos.
in the Odivo group, the majority of patients (89%) were able to receive a relative dose intensity of 90%.
patients treated with Odivo, the rates of adverse events (TRAEs) associated with treatment at all levels were 71% and 13%, respectively, and in the placebo group 46% and 6%, respectively.
in the Odivo group, less than 10 percent of patients had severe TRAEs (all levels: 8 percent, 3-4 levels: 5 percent), and the placebo group had 3 percent and 1 percent, respectively.
in both groups, the rate of drug suspension due to any level of TRAEs was lower (Odivo group: 9%, placebo group: 3%).
the study, esophageal cancer and gastroesophageal cancer became the second tumor that Odivo has been shown to benefit patients as an auxiliary treatment after melanoma.
is expected to become a new standard treatment for this type of patient-assisted treatment. Dr. Ian M. Waxman, Head of Research and Development, Gastrointestinal Cancer Group,
", said, "The progress of this study shows that Shishi Shiguibo is committed to evaluating the effectiveness of innovative therapies in the early stages of disease, with the hope of making a more far-reaching impact on preventing disease recurrence and improving patient prognostication."
months, we look forward to discussing the encouraging findings of CheckMate-577 with health authorities around the world.
" About CheckMate -577CheckMate -577 is a Phase III, randomized, multi-center, double-blind clinical study designed to assess the efficacy and safety of Odivo as an auxiliary treatment for patients with removable esophageal cancer and gastroesophageal connecting cancer who do not reach full pathological remission after new assisted synchrugal chemotherapy (CRT).
end of the study was disease-free lifetime (DFS) and the secondary endpoint was total survival (OS).
After receiving new assisted synchronous chemotherapy and a complete tumor excision (also known as triple therapy), 794 patients were randomly assigned to the placebo group (N-262) or Odivo group (N-532), and the Odivo group received Odivo2 40 mg, every 2 weeks intravenous drips, after 16 weeks of continuous medication, sequentia Odivo 480 mg, every 4 weeks intravenous drips, until the disease relapses, insatiable toxicity or the patient withdraws informed consent, the total duration of treatment is up to one year.
about esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of death.
2018, there will be about 572,000 new cases and more than 508,000 deaths from esophageal cancer worldwide.
, esophageal cancer is the sixth most common cancer and the fourth leading cause of cancer death, after lung, stomach and liver cancers.
squamous cell carcinoma and adenocarcinoma remain the two most common types of esophageal cancer, accounting for nearly 85% and 15% of the total number of esophageal cancer patients, respectively.
most people with esophageal cancer are terminally ill at the time of diagnosis and their daily lives, including their diet, are affected.
about stomach cancer Is the fifth most common cancer in the world and the third leading cause of death.
2018, there will be more than 1,000,000 new cases of stomach cancer and about 783,000 deaths worldwide.
broad definition of stomach cancer, including gastroesophageal joint (GEJ) cancer, which forms at the junction of the stomach and esophageal, can be attributed to stomach cancer.
, compared with stomach cancer, the prevalence of gastroesophageal cancer is low, but it is increasing.
About Odivo Odivo was approved as the world's first PD-1 inhibitor in July 2014 and has been approved in 66 countries and territories for a total of 11 tumors1, covering lung, head and neck, stomach, esophageal, liver, kidney, colorectal, urethra, melanoma, Hodgkin's lymphoma, thoracic tumors, and more than 590,000 patients worldwide.
Odivo is the first approved immuno-oncology drug approved in China, currently approved a total of 3 adaptations in China, except for the following adaptation certificates have not yet been approved: 1) for the treatment of skin growth factor recipient (EGFR) gene mutation negative and mesozoic lymphoma kinase (ALK) negative, previously received platinum-containing chemotherapy after disease progression or insirability of local late-stage or metastatic non-small cell lung cancer (NCLC) ) adult patients; 2) patients with relapsed or metastatic head and neck squamous cell carcinoma (SCCHN) who have developed the disease during or after treatment with platinum-containing programs and who have positive expression of tumor PD-L1 (expression of PD-L1 tumor cells by 1%); and 3) for the treatment of patients with advanced or relapsed stomach or gastroesophageal cancer who have previously received two or more systemic treatment options.
Odivo is the only PD-1 inhibitor developed directly by nobel laureates in physiology or medicine.
Meishi Shiguibao owns the exclusive use of Dr. Ben Yu's PD-1 patent.
Note 1: Odivo-based immunodiotherapy and immunotherapy combined treatment.